Marapharm Ventures Inc. (OTCQB: MRPHF) (MDM.CN) Breaking News

May 8, 2017

Read a Special Report for
Marapharm Ventures Here

Marapharm Ventures Inc. "Marapharm" announces a financial update on the 2nd anniversary of trading as a public company - it has raised $22,917,150.00
 

KELOWNA, British Columbia, May 8, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) was listed on the CSE and began trading on May 8, 2015, with subsequent listings on the OTCQB and the FSE.

Marapharm has raised $22,917,150.00 (share source: Computer Share; Transfer Agent). The proceeds have been raised by private placements, and the exercise of options and warrants as a public company. The first tranche of the bond offering, announced on February 28, 2017 is closed, the total is USD $1,280,000.00. There is $4,220,000.00 remaining and is available for subscription. There are two warrant series left to be exercised for a potential of $4,951,200.00. Marapharm has approximately $5 million cash at the present time.

 Marapharm has purchased 13.6 acres of industrial land with buildings in Washington State which is approved for marijuana cultivation, processing and as a cannabis campus

 Marapharm has purchased 7 acres of industrial property in Las Vegas,
Nevada with buildings approved for marijuana cultivation and processing

 Marapharm has purchased industrial properties in California approved for marijuana cultivation and processing

 Marapharm has acquired and or has conditional applications for up to 11 cannabis licenses in the United States and Canada

 Marapharm purchased 15 million shares and warrants of Veritas Pharma Inc., a public company

 Marapharm owns Marapharm Delivery Service for medical marijuana deliveries

 Marapharm owns www.marapharm.tv
"We have worked hard during the past two years, and now, Marapharm is ready to grow. We have created a strong infrastructure and shareholder base. We have licenses, property and buildings.”

“Coupon and convertible bonds have been used to raise construction money. Several lenders and investors have presented financing proposals for further construction options including an $80 million dollar USD conditional commitment. We will continue to scrutinize all proposals to ensure the best decisions are made for Marapharm.”

“The past 2 years have been significant. We have set a foundation for long term success and expansion in this exciting market. The next few years are going to be historical!” Linda Sampson, Marapharm CEO.

Marapharm has traded 98,923,854 million shares on three stock markets for a value of $126,564,847.00 CDN in its first two years of public trading.

On the CSE Marapharm has traded 53,542,926 shares since its trading debut on May 8, 2015 for a value of $60,504,667.91 CDN. Marapharm has traded 13,003,894 shares since its trading debut on September 1, 2015 on the OTCQB for a value of $12,738,030.71 USD. Marapharm has traded 32,377,034 shares since its trading debut on June 28, 2015 on the FSE for a value of $32,246,997 EUR. (source: Stockwatch and the Frankfurt Stuttgart)
ABOUT MARAPHARM VENTURES INC.
www.marapharm.com

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol “MDM” on the Canadian Securities Exchange, and in the United States, under the ticker symbol “MRPHF” on the OTCQB, and in Europe, under the ticker symbol “2M0” on the FSE.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.


STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

FOR FURTHER INFORMATION:
www.marapharm.com contact 778-583-4476 email info@marapharm.com

Source: Marapharm Ventures Inc.

_________________________________________________
Recent MARAPHARM News

Marapharm Ventures Inc. 'Marapharm' has Hired Gide LLC for Government and Stakeholder Relations for Potential Delivery Services and Cannabis Vending Machines  
 

KELOWNA, British Columbia, May 3, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) "To ensure brand integrity, we want open and direct communication with government and community stakeholders, specifically where we do business in the transportation, delivery and vending divisions. Gide LLC will work to the broadest acceptance and potential implementation for these in a variety of markets," said Linda Sampson, Marapharm CEO.

Gide LLC is an advisor, architect and executor of public affairs strategies. They combine traditional government relations with contemporary public interest and media campaigns. In addition to dealing with current situations, Gide LLC works to pass laws that can make Marapharm more profitable and overturn laws that impede it. Gide LLC will activate meetings with city officials and managers to explain vending and delivery methods. Key stakeholders include casinos, supervisors, city council members, mayors and governing boards. Gide LLCs approach is to provide Marapharm with a strong voice to engage and enhance it's business in strategic growth areas and states.

"We are looking forward to working with Gide LLC because they see our vision too, which is for Marapharm to continue to grow and perfect it's businesses in the United States," said Linda Sampson, Marapharm CEO.

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com/

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol "MDM" on the Canadian Securities Exchange, and in the United States, under the ticker symbol "MRPHF" on the OTCQB, and in Europe, under the ticker symbol "2M0" on the FSE.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

STOCK EXCHANGES: Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release constitute forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

FOR FURTHER INFORMATION:
Linda Sampson
CEO
+1-778-583-4476
E-mail: info@marapharm.com
http://www.marapharm.com

SOURCE Marapharm Ventures Inc.
 

Marapharm Ventures Inc. "Marapharm" Announces the Acquisition of a Second Property With Approved Conditional Use Permit (CUP) Located in Desert Hot Springs, California, for Cannabis Cultivation
 

KELOWNA, British Columbia, May 2, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) announces that it has entered into an agreement to purchase 7.02 acres located in Desert Hot Springs, CA and that the development has an approved CUP for 102,125 square feet of cannabis cultivation and processing. The purchase price is $2.5 million USD. The agreement is contingent for 60 days, for approval of up to 40,000 square feet of interim facilities, for trailer pods to be brought to the property for interim growing before construction. An interim plan for cultivation was previously approved by the City but was not continued. MSA Consulting Inc. is contracted to renew the process.

Marapharm announced April 17, 2017 that it purchased, without contingencies, 1.22 acres of property located in Desert Hot Springs, CA, zoned industrial and approved for a CUP of 29,193 square feet, for cultivation and processing. Items which are completed in the development process include the required orientation meeting, development agreement, conditional use permit, preliminary review (street improvements, water retention and capacity, utilities, setbacks, grading, fore suppression, fences, walls, etc.), agreement submissions, application preparations submissions, architecture and landscape review, environmental submissions and review, city attorney review, planning commission approvals, city council and several other steps.

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol 'MDM' on the Canadian Securities Exchange, and in the United States, under the ticker symbol 'MRPHF' on the OTCQB, and in Europe, under the ticker symbol '2M0' on the FSE.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

STOCK EXCHANGES: Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

For Further Information:
http://www.marapharm.com
Linda Sampson
CEO
+1-778-583-4476
E-mail: info@marapharm.com
SOURCE Marapharm Ventures Inc.

Marapharm Ventures Inc. 'Marapharm' Announces an Online News Channel for Awareness of the Sector and of Marapharm
 

KELOWNA, British Columbia, April 28, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) is pleased to announce that it will be launching http://www.marapharm.tv on or before June 15, 2017.

"Marijuana is news. I did an interview on http://www.rightedition.com that has had in excess of 250,000 views. The success of the interview prompted us to look into the viability of doing regular media programs on the industry and on Marapharm. We have a studio, technical team and several prepared scripts. Filming is scheduled to begin May 4, 2017. Our performa indicates that millions of viewers could be reached including investors, users and those who are just interested in news of the marijuana industry. They will then also become aware of Marapharm. There will be an investor's relation and market report of Marapharm's stock activity at the end of each program.

In 2016, Cowen and Company, a Multi Sector Equity Research Group stated that the legal US cannabis markets to be at $6 billion (prior to California's passage of adult use) another $25 billion is spent in the black market. The average monthly searches for 'marijuana' on Google are more than 1 million per month (Source http://www.leafly.com April 26, 2017). These statistics were a factor when researching to create an online video channel for branding and awareness of Marapharm," Linda Sampson, Marapharm CEO.

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol 'MDM' on the Canadian Securities Exchange, and in the United States, under the ticker symbol 'MRPHF' on the OTCQB, and in Europe, under the ticker symbol '2M0' on the FSE.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

STOCK EXCHANGES: Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS: Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

For Further Information:
http://www.marapharm.com
Linda Sampson, CEO,
+1-778-583-4476
email info@marapharm.com
SOURCE Marapharm Ventures Inc.

Marapharm Ventures Inc. ("Marapharm") Completes Independent Valuation of Las Vegas, Nevada, Cannabis Project
 

KELOWNA, British Columbia, April 7, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) is pleased to announce that it has received an independent calculation/valuation report with respect to an appraisal of assets conducted in December of 2016, for corporate planning purposes and in preparation for construction of the facility and subsequent production (cultivation) and processing operations. RWE Growth Partners Inc. ("RWE") was engaged to assess the market value of the 7-acre property and associated 3 cannabis licenses controlled by Marapharm in Las Vegas, Nevada.

The valuation of the property and licenses, prior to the commencement of construction and in advance of production, was $3,500,000 USD (~$4,700,000 CDN). Since the preparation of this report, construction has begun and there has been an additional $1 million USD (~$1,300,000 CDN), invested in applications, legal fees, wages, wet and dry utility deposits, structural components, and permit bonds. "Based upon this report and not including the subsequent costs incurred to move the project forward, we calculate that we have more than $4.5 million USD (~$6 million CDN) of realizable equity in this project at the present time, "states Linda Sampson, Marapharm CEO.

The RWE report provides the following valuation and methodology:

Considering FOUR criteria for the highest and best use, namely Physical Possibility. Legal Considering FOUR criteria for the highest and best use, namely Physical Possibility. Legal Permissibility. Financial Feasibility and Maximum Profitability, RWE determined the most appropriate methods to value MMJ licenses is by using the Income Approach.

An extract of the RWE report is available on Marapharms website at http://www.marapharm.com under the tab "Investors" and will also be filed on SEDAR.

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com

Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol "MDM" on the Canadian Securities Exchange, and in the United States, under the ticker symbol "MRPHF" on the OTCQB, and in Europe, under the ticker symbol "2M0" on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

STOCK EXCHANGES: Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS: Certain statements contained in this news release constitute forward-looking statements, specifically with respect to the disclosure contained in the valuation report. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon. Specifically, Marapharm may not be able to realize the valuation of its Nevada property, or extract such value from its Nevada property, as disclosed in the valuation report and there is no assurance that any business objectives with respect to, or plans for, the Nevada project will proceed to completion or be successful.

FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, +1-778-583-4476, info@marapharm.com

SOURCE Marapharm Ventures Inc.

Marapharm Ventures Inc., Kelowna, B.C. ("Marapharm"), Announces a Laboratory for Research and Development of Marijuana for its Washington Property
 

KELOWNA, British Columbia, April 3, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) is pleased to announce that it has entered into an agreement with AlphaPheno Inc. ("Alpha") of Washington state to build a laboratory on the 13.6-acre-site of Marapharm's property. Alpha, in conjunction with Veritas Pharma Inc., an emerging discovery and IP development company, will enter into a joint venture arrangement for the research and development ("R&D") business. Alpha holds a Tier 3 cultivation and processing license and therefore is permitted to apply for and hold an R&D license. With an extensive list of cannabis genetics and existing cultivation space, Alpha is applying for a marijuana research license to leverage the synergy with Veritas in the U.S. market. The agreement is conditional on acceptance of the application. The license will provide the holder with the ability to produce, process, and possess marijuana to test chemical potency and composition levels, to conduct clinical investigations of marijuana-derived drug products, to conduct research on the efficacy and safety of administering marijuana as part of medical treatment, and to conduct genomic and or agriculture research. Veritas will provide the R&D thesis, programs, equipment, and laboratory standards and protocol for a focused R&D approach. Veritas will also determine the key qualified personnel required to execute these programs. A new laboratory will be constructed within Marapharm's buildings, which are occupied by Alpha.

"The R&D laboratory will be a welcome addition to the cannabis campus and is a reason for other cannabis businesses to look to us for a facility. Veritas, (VRT and VRTHF), is a public company, of which Marapharm owns 15 million shares, so entering into a joint venture with Veritas represents another level of commitment", said Linda Sampson, Marapharm's CEO.

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com

Construction photos and videos can be accessed through the Marapharm website. Marapharm's common shares are publicly traded in Canada, under the ticker symbol "MDM" on the Canadian Securities Exchange, and in the United States, under the ticker symbol "MRPHF" on the OTCQB, and in Europe, under the ticker symbol "2M0" on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

STOCK EXCHANGES:  Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:  Certain statements contained in this news release constitute forward-looking statements, specifically with respect to the proposed joint venture arrangement with AlphaPheno Inc. and Veritas Pharma Inc. and the construction of a laboratory on Marapharm's Washington property. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon. Specifically, Marapharm may not be able to complete the construction of the laboratory on the terms proposed and there is no assurance the joint venture arrangement will proceed to completion or be successful.

FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, +1-778-583-4476 info@marapharm.com

SOURCE Marapharm Ventures Inc.

Marapharm Ventures Inc., Kelowna BC, "Marapharm" Announces $3,570,000 of Warrants Exercised for First Quarter of 2017
 

KELOWNA, British Columbia, March 31, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) is pleased to announce that $3,570,000.00 has been received from the exercise of warrants in the first quarter of 2017.

Linda Sampson, Marapharm CEO notes, "We are very pleased that our shareholders have the confidence in Marapharm by increasing their ownership positions, through the exercising of their warrants. We will use this $3,570,000 million for further development and working capital. We will continue to search for acquisition opportunities, particularly in California."

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com

Construction photos and videos are on the web site. Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for it's land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com) and Sedar website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

STOCK EXCHANGES:  Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:  Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

Website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, 778-583-4476, info@marapharm.com
SOURCE Marapharm Ventures Inc.

Marapharm Ventures Inc. "Marapharm" Provides Construction Updates for 13.6 Acres of Industrial Land and Buildings Located in Washington State and 7 Acres in Nevada
 

KELOWNA, British Columbia, March 11, 2017 /PRNewswire/ --  Marapharm Ventures Inc. (OTCQB: MRPHF), (CSE: MDM), (FSE: 2M0) ("Marapharm" or the " Company") (http://www.marapharm.com/) "Nevada: December 19, 2016 Marapharm announced an update of construction on the 7 acres of property we own in Las Vegas. Some of the items and dates given then had time changes but the end date of March 30th for the buildings to be erected at the present time is on target. Photos and a video from a few days ago are posted on the website under the Las Vegas Project tab. The buildings are on the ground and the ground is being prepared. The plan is still to be growing by the end of April. The planning for the buildout of the entire 360,000 square feet of buildings is underway. All cultivation inventories have been pre-sold." Linda Sampson, Marapharm CEO.

Washington: March 9, 2017 the Washington State LCB (Liquor Control Board) have approved the plans submitted for the construction and renovation of one of the buildings located on the 13.6 acres of land recently purchased. The approval is for the 30,000 square foot building and comes with the requirement for Marapharm to provide regular photo updates of the progress to the LCB. The county is now reviewing the capping of the fire sprinklers for approval as part of the overall process.

News Release Summary References, for Washington State:

February 27, 2017 Marapharm announced steps underway to construct / create a cannabis campus. February 12, 2017 Marapharm announced that its subsidiary Marapharm Washington, LLC "Washington WA" had entered into an agreement to purchase 13.6 acres of industrial, highway frontage property located a few minutes south of the Canadian border for $4.2 million US. The transaction closes February 28, 2017. Previously, on June 16, 2016, the Company announced that it had concluded a deal for a lease of a 30,000 square foot building and an option to purchase 13.6 acres of industrial property located in Whatcom County, Washington State. Further, on August 17, 2016, Marapharm announced that Marapharm WA had closed on the purchase of the assets of a 30,000 square foot operating tier 3 marijuana cultivation and processing facility, located in Washington State and on September 27, 2016 and November 1, 2016 provided updates with regard to the Washington operations. Marapharm has been making lease payments on the property and has chosen to act on the option to purchase the land.

ABOUT MARAPHARM VENTURES INC.

http://www.marapharm.com

Marapharm (OTCQB: MRPHF) trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com) and Sedar website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, 778-583-4476 info@marapharm.com

STOCK EXCHANGES:  Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:  Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, +1-778-583-4476 info@marapharm.com

SOURCE Marapharm Ventures Inc.

----------------------------------------------------------------------------------------------
About Marapharm Ventures Inc.

MARAPHARM
Marapharm Ventures Inc. is a public company which invests in health and wellness, including medical and recreational marijuana.

Corporate Overview

Marapharm Ventures Inc. (“ Marapharm” or the “Company”) is a developmental stage publicly traded medical marijuana company with operations based in British Columbia.

Through its wholly owned operating subsidiary Marapharm Inc., the Company has applied to Health Canada to become a licensed producer under the Marijuana for Medical Purposes Regulations (MMPR) issued pursuant to the Controlled Drugs and Substances Act (Canada). Marapharm’s initial facility, a proposed 22,000 sq.ft state-of-the-art designed-to-suit cultivation facility, will be constructed on an 11 acre leased site in Kelowna, British Columbia.

The Company’s growth strategy will be to build facilities or acquire licenses in the United States, determined by identifying opportunities and researching the direction and location of sales. The company has currently focused its attention on opportunities in Nevada and Washington.

Land has been purchased in Apex Business Park in the City of North Las Vegas, Nevada, for purposes of building a cultivation and production facility that will house three medical marijuana licenses.

In Washington, the Company has an opportunity to lease a facility to an I-502, tier 3 license holder. The licensee holds a production license for 30,000 sq’ and a processing license with unlimited potential.

Marapharm has also purchased and is developing an all-natural hemp oil product line called, Maragold, which will be ready for market within a few months.

Company Highlights

Innovative – Suite of innovative cannabis products and services that will provide the company with a first-leader advantage in under-serviced and emerging markets and growth sectors.

Strategic– Dual growth strategy in Canada and the U.S.

Sales – In Canada - will be proprietary internet, mobile and web-based processes to create virtual store-front opportunities for approved buyers. In the U.S.: Nevada – we have entered into LOI’s with 3 dispensaries for our entire production. Colorado – This facility has both a medical and recreational dispensary. California – entered into an LOI for a dispensary.

Production – Brand new, energy efficient facilities have been designed to provide maximum product yield at lower cost.

Management – Proven management group that possess extensive business, cultivation and quality assurance experience.

Security – Security personnel and state-of-the-art systems to govern access to production departments and to support the required record-keeping responsibilities expected by regulators.

Market Opportunity

The North American market for legalized medical and adult use marijuana has been projected to conservatively exceed $11.5 billion by 2018. The market for medicinal use in Canada was estimated at $144 million in 2014 and expected to grow by 23% per year to $1.3 billion over the next 10 years.

In the U.S. the legal cultivation of medical and adult use marijuana is a field set to bring prosperity due to changes at the regulatory level combined with the groundswell of acceptance for the idea of use itself. Currently there are 23 states that have legalized medical marijuana, 4 states have legalized adult use marijuana and many more states (including Nevada) have ballot measures in place for the November 2016 elections. In Canada the newly established MMPR has opened up the market to large scale production and pending the outcome of the 2015 election could be legalized.

FORWARD LOOKING STATEMENT
This page contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “ACT”). In particular, when used in the preceding discussion, the words “pleased”, “plan”, “confident that”, “believe”, “expect”, and/or “intend to”, and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings and other risks. This document is not an offer to buy or sell securities. Securities may only be offered by private placement subscription agreement.

Operations Management Team

Linda Sampson, Director and CEO, Marapharm Inc.

Linda Sampson brings a dynamic energy, a wealth of talent, and a multi-layered business expertise to the Company. She is a business start-up professional, with a history of ground-up to successful ventures. An accomplished sales professional, marketer, designer, developer, with international experience, she brings superior business branding skills and internal administrative talents to Marapharm.

Markus Heinrichs PhD – Quality Assurance

Markus Heinrichs is currently teaching at the Okanagan College. He has been a faculty member at renowned post-secondary institutions such as Simon Fraser University, the University of British Columbia Okanagan, the University of the Fraser Valley, Kwantlen College, Selkirk College, in addition to lecturing at Technische Universität München, within school district #78 in the Fraser-Cascade region, and at the Climate Impacts Research Centre. Markus completed his PhD at the University of Victoria, a Master of Science, Professional Development Program, Post Baccalaureate Diploma, and his undergraduate studies (Bachelor of Science) at Simon Fraser University . Other credentials include a Diploma of Technology, from the Northern Alberta Institute of Technology Edmonton, in addition to publishing several scholarly articles. His primary research interests lie in the biological sciences. Markus will oversee quality assurance and good production practises at Marapharm.

Jason Lorenson – Head Grower

Jason Lorenson is perfectly suited for the position of Head Grower. Jason has constructed nine medical marijuana grow facilities from the ground up, and has been involved in every level of their development. He is an innovator and has designed and created growing systems that are capable of producing 2+ lbs per light, cloning systems with a 98% success rate as well as a commercial grade manicuring system that produces an excellent final product. He is devoted to the production of excellent quality, uncontaminated medical marijuana for patients choosing this method of treatment. As a production manager of B.C. Bud Depot, Jason facilitated “transparency tours” allowing community leaders, Police, and Government representatives to tour their facility in an effort to facilitate good dialogue within the community.

Jeannette E Ball – Good Production Practices

Jeannette Ball is currently the most senior technician in the sterile processing department at one of the largest hospitals in British Columbia. As part of the Quality Assurance of her department she has to validate and accurately document data on each piece of equipment used in the sterilization process and answers to the Ministry of Health. In 2006, she authored the manual and handbook, “Sterile Processing Department”. This document outlines every procedure, duty, function and level of sterilization performed in this department. Jeannette will assist in developing all of the Standard Operating Procedures for Marapharm.

Randy Kolibaba - Security Professional Consultant

Randy Kolibaba is a results-driven senior executive having distinguished service in the Royal Canadian Mounted Police and the United Nations. He has had proven success promoting; efficiency, growth and profitability in diversified policing and protective services, combined with extensive international expertise. Noted for abilities in leadership, Threat/Risk assessment, Vulnerability analysis, Disaster Planning and Management, Major Crimes investigations, Project management, Strategic Planning, Workplace safety, Employee development and Change management, Diversified uniform and plain clothes background that includes general duty patrol and investigation, road safety and traffic law enforcement, Nationally recognized First Nations policing experience. Legally trained and appointed by the Federal Court of Canada as an adjudicator for the RCMP, extensive command experience at the non-commissioned and commissioned officer level. He has established expertise in labour relations. Randy has received numerous awards including the Queens Diamond Jubilee medal for Outstanding Service to Canada (2012), Canada 125 Medal for Outstanding Service to Canada's First Nations (1994), Canadian Peacekeeping Medal (2000), United Nations Peacekeeping Medal (Kosovo 2000) as well as an RCMP Long Service Medal.

Marapharm Canada
Marapharm Inc., a wholly owned subsidiary of Marapharm Ventures Inc., began assembling people and property in 2014 for an application and future build out on property located in Kelowna British Columbia, Canada. The property is 11 acres in size and the Provincial government has confirmed that the zoning is a legal and proper to use for medical marijuana production. The City of Kelowna however has yet to establish bylaws for the new industry to reflect the governments order and Marapharm in turn is looking at other jurisdictions for a change in venue application to Health Canada should it be deemed nessasary to expedite the process.

In September 2015 Marapharm's application to Health Canada for an MMPR license progressed to the Security Clearance Process stage. In February 2016 this stage was approved. According to Health Canada's web site there are several stages to the application process. The security clearance stage being a significant milestone in that process. Marapharm intends to commence construction as soon as possible once the license application has been approved in it's entirety.

The Marijuana for Medical Purposes Regulations (MMPR) came into force in June 2013. The regulations create conditions for a commercial industry that is responsible for the production and distribution of marijuana for medical purposes. They also make sure that Canadians with a medical need can access quality controlled marijuana grown under secure and sanitary conditions.

Marapharm Las Vegas

Marpahrm's wholly-owned subsidiary Marapharm Las Vegas LLC, in advance of the planned 380,000 sq. ft. main cultivation facility, will commence construction of two 5,000 sq. ft. medical marijuana complexes on the 5.9 acres it owns in the Apex Industrial Park, located north of Las Vegas, Nevada. This facility will provide interim product to local dispensaries. The buildings are ordered and will be erected in approximately six to eight weeks. The facilities will be used for hiring, training and cultivation during the construction of the main facility.
Cultivation from each of the initial buildings will produce an estimated US$3,500,000 in revenue and a net profit of US$2,300,000 per building. The product from the initial facilities has already been contracted by agreement to a dispensary in Las Vegas, Nevada. Further, the entire cultivation of the 300,000 sq. ft. of canopy development is contracted to several dispensaries located in Las Vegas, Nevada.

Situated along Interstate 15, Apex is just 25 minutes from McCarran International airport and within five hours from the Port of Los Angeles. Apex has the potential to become one of the predominant industrial developments in the western United States. Access to major North American cities is readily available via Highway 93 and the Union Pacific Railroad. The park offers access to municipal groundwater, high pressure gas and an abundance of power supplied by the five power generation stations within the park’s boundaries.

Medical marijuana was legalized in the state of Nevada on November 7, 2000. In 2013, the Nevada legislature allowed for safe, regulated access to cannabis. At the end of 2014, there were only 8,000 registered medical marijuana users and by the end of 2015 it is anticipated that the number will have grown to 50,000. Aside from these users, Nevada law allows any non-resident who carries a valid medical marijuana card in their home state to present their card in Nevada and purchase their marijuana while visiting. Reported average medical use is between one and two ounces (28-56 grams) per month. It is anticipated that retail prices will be from US$10-$30 per gram.

Recreational marijuana is on the ballot in Nevada for the 2016 election and polls already show 54% in favour of legalization.

Marapharm Ventures Inc. has a market-leading plan, with a marketing program established for the emerging market of medical marijuana. The North American market for marijuana, if fully legalized could exceed 40 billion dollars per year.

Stock Exchanges

Canadian Securities Exchange “CSE” website: MDM-Marapharm Ventures Inc Ticker symbol: MDM
Nasdaq – OTCQB markets “OTCQB” website: MRPHF-Marapharm Ventures Inc Ticker symbol: MRPHF
Frankfurt Stock Exchange “FSE” website: 2M0-Marapharm Ventures Inc Ticker symbol: 2M0 (zero)

SOURCE: www.marapharm.com

Disclaimer